Trial Profile
International, randomized, double blind, phase 3 trial of Axitinib (AG-013736) versus placebo given in advanced non small cell lung cancer patients receiving cisplatin and gemcitabine as first line treatment.
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 12 Mar 2011
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 29 Jun 2009 New trial record